A detailed history of State Of Wisconsin Investment Board transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, State Of Wisconsin Investment Board holds 92,329 shares of RXRX stock, worth $592,752. This represents 0.0% of its overall portfolio holdings.

Number of Shares
92,329
Previous 100,554 8.18%
Holding current value
$592,752
Previous $754,000 19.36%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$5.92 - $8.6 $48,692 - $70,735
-8,225 Reduced 8.18%
92,329 $608,000
Q2 2024

Aug 14, 2024

SELL
$7.35 - $10.05 $33,604 - $45,948
-4,572 Reduced 4.35%
100,554 $754,000
Q1 2024

May 14, 2024

SELL
$9.13 - $15.52 $22,861 - $38,862
-2,504 Reduced 2.33%
105,126 $1.05 Million
Q4 2023

Feb 12, 2024

SELL
$5.09 - $10.79 $11,040 - $23,403
-2,169 Reduced 1.98%
107,630 $1.06 Million
Q3 2023

Nov 14, 2023

SELL
$6.59 - $15.86 $16,376 - $39,412
-2,485 Reduced 2.21%
109,799 $839,000
Q2 2023

Aug 14, 2023

BUY
$4.56 - $9.94 $282,596 - $616,011
61,973 Added 123.18%
112,284 $838,000
Q1 2023

May 15, 2023

BUY
$6.42 - $9.64 $26,514 - $39,813
4,130 Added 8.94%
50,311 $335,000
Q4 2022

Feb 14, 2023

SELL
$7.16 - $12.7 $188,608 - $334,543
-26,342 Reduced 36.32%
46,181 $356,000
Q3 2022

Nov 14, 2022

BUY
$7.83 - $13.6 $218,292 - $379,154
27,879 Added 62.45%
72,523 $772,000
Q2 2022

Aug 15, 2022

SELL
$5.04 - $9.26 $542,586 - $996,894
-107,656 Reduced 70.69%
44,644 $363,000
Q4 2021

Feb 11, 2022

BUY
$16.14 - $21.86 $2.02 Million - $2.73 Million
125,000 Added 457.88%
152,300 $2.61 Million
Q2 2021

Aug 12, 2021

BUY
$18.0 - $37.42 $491,400 - $1.02 Million
27,300 New
27,300 $996,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.16B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track State Of Wisconsin Investment Board Portfolio

Follow State Of Wisconsin Investment Board and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wisconsin Investment Board with notifications on news.